Novo Nordisk revises forecast upward

Novo Nordisk A/S has revised upward its financial forecast for 2017 following a good performance by Victoza, its glucagon-like peptide-1 (GLP-1) medicine for diabetes in the first quarter. The outlook for both sales and operating profit have been raised slightly.

Full text available to subscribers only. Click here for information on subscribing to MedNous.